FibroBiologics Inc. (FBLG), a clinical-stage biotechnology company, on Monday released the first batch of the CYWC628 drug product for the Phase 1/2 clinical trial to treat diabetic foot ulcers (DFUs).
CYWC628 is an investigational fibroblast-based therapy, manufactured by the company according to current good manufacturing practices (cGMP), as outlined by the U.S. food and drug administration (FDA).
The Phase 1/2 trial will evaluate the safety, tolerability, and preliminary efficacy of CYWC628 in treating patients with DFUs. The release of the drug to clinical testing sites will facilitate the progress of the study.
FBLG is trading at $1.35, down 7.53%.
For comments and feedback contact: editorial@rttnews.com
Business News
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.